ClinicalTrials.gg

Program

ponesimod

Also written as “Ponesimod”, “ACT-128800” and “Ponesimod 10 mg”.

Its studies are mostly in Multiple Sclerosis · Psoriasis · Colitis, Ulcerative · Bronchiolitis Obliterans Syndrome, led by 2 companies.

Furthest: phase 3, since Apr 21, 201516 company-led studies, 2 open or runningNext primary completion: Aug 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson140 open or runningphase 3since Apr 21, 2015Feb 26, 2009none ahead
Vanda Pharmaceuticals22 open or runningphase 3since Jan 20, 2026Jan 20, 2026Aug 2028phase 3 · NCT07362017

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Feb 26, 2009.

  1. Mar 24, 2010Phase 2 study in Multiple SclerosisJohnson & Johnson · NCT01093326 · 353 enrolled · United States, Austria, Bulgaria and more
  2. Sep 22, 2010Phase 2 study in PsoriasisJohnson & Johnson · NCT01208090 · 326 enrolled · Austria, Belgium, Bulgaria and more
  3. Jan 6, 2014Phase 1 study in Safety and TolerabilityJohnson & Johnson · NCT02029482 · 16 enrolled · United Kingdom
  4. Feb 19, 2014Phase 1 study in HealthyJohnson & Johnson · NCT02068235 · 17 enrolled · United Kingdom
  5. Apr 29, 2014Phase 1 study in PharmacokineticsJohnson & Johnson · NCT02126956 · 6 enrolled · Switzerland
  6. May 9, 2014Phase 1 study in HealthyJohnson & Johnson · NCT02136888 · 116 enrolled · United States
  7. Aug 21, 2014Phase 1 study in HealthyJohnson & Johnson · NCT02223832 · 20 enrolled · United States
  8. Apr 21, 2015Phase 3 study in Multiple SclerosisJohnson & Johnson · NCT02425644 · 1,133 enrolled · United States, Belarus, Bosnia and Herzegovina and more
  9. Apr 28, 2015Phase 2 study in Bronchiolitis Obliterans SyndromeJohnson & Johnson · NCT02461134 · 1 enrolled
  10. Aug 25, 2016Phase 3 study in Multiple SclerosisJohnson & Johnson · NCT02907177 · 136 enrolled · United States, Australia, Austria and more
  11. Jul 20, 2017Phase 3 study in Multiple SclerosisJohnson & Johnson · NCT03232073 · 877 enrolled · United States, Belarus, Bosnia and Herzegovina and more
  12. Sep 21, 2022Phase 1 study in HealthyJohnson & Johnson · NCT05552196 · 28 enrolled · Belgium
  13. Jan 20, 2026Vanda Pharmaceuticals's first study: phase 3 study in PsoriasisNew to Vanda PharmaceuticalsVanda Pharmaceuticals · NCT07362017 · 300 planned · United States
  14. Jun 30, 2026Phase 3 study in Colitis, UlcerativeVanda Pharmaceuticals · NCT07686081 · 150 planned · United States

Ahead

  1. Aug 2028Primary completion: phase 3 study in PsoriasisVanda Pharmaceuticals · NCT07362017
  2. Apr 2029Primary completion: phase 3 study in Colitis, UlcerativeVanda Pharmaceuticals · NCT07686081

TargetBeta

S1PR1 →read by rule
“An orally available sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) agonist that acts as a functional antagonist, ”NCIt, by rule
“Sphingosine 1-phosphate receptor Edg-1 agonist”ChEMBL 37, by rule

Other programs on S1PR1

ProgramCompanyFurthest phaseStudies
fingolimodruleNovartisphase 455
etrasimodrulePfizerphase 321
cenerimodruleViatrisphase 314
mocravimodruleNovartisphase 35

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07686081Colitis, Ulcerative · United States3RecruitingVanda PharmaceuticalsApr 2029150
NCT07362017Psoriasis · United States3RecruitingVanda PharmaceuticalsAug 2028300
NCT05552196Healthy · Belgium1CompletedJohnson & JohnsonMar 5, 202328
NCT03232073Multiple Sclerosis · United States, Belarus, Bosnia and Herzegovina and more3CompletedJohnson & JohnsonJan 16, 2024877
NCT02907177Multiple Sclerosis · United States, Australia, Austria and more3TerminatedJohnson & JohnsonMar 26, 2020136
NCT02461134Bronchiolitis Obliterans Syndrome2TerminatedJohnson & JohnsonMar 2, 20171
NCT02425644Multiple Sclerosis · United States, Belarus, Bosnia and Herzegovina and more3CompletedJohnson & JohnsonMay 16, 20191,133
NCT02223832Healthy · United States1CompletedJohnson & JohnsonApr 200920
NCT02136888Healthy · United States1CompletedJohnson & JohnsonFeb 2012116
NCT02126956Pharmacokinetics · Switzerland1CompletedJohnson & JohnsonApr 20096
NCT02068235Healthy · United Kingdom1CompletedJohnson & JohnsonNov 201417
NCT02029482Safety and Tolerability · United Kingdom1CompletedJohnson & JohnsonJun 201016
NCT01208090Psoriasis · Austria, Belgium, Bulgaria and more2CompletedJohnson & JohnsonOct 31, 2012326
NCT01093326Multiple Sclerosis · United States, Austria, Bulgaria and more2CompletedJohnson & JohnsonSep 6, 2023353
NCT01006265Multiple Sclerosis · United States, Australia, Austria and more2CompletedJohnson & JohnsonJun 1, 2011464
NCT00852670Plaque Psoriasis · Austria, France, Germany and more2CompletedJohnson & JohnsonJul 200966

How it is read

Names in the registry

  • “Ponesimod”, 6 entries
  • “ACT-128800”, 5 entries
  • “Ponesimod 10 mg”, 2 entries
  • “Ponesimod 20 mg”, 2 entries
  • “Ponesimod 40 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.